Senseonics Announces The Last Patient Completion Of The 365-Day ENHANCE Pivotal Clinical Study
Portfolio Pulse from Benzinga Newsdesk
Senseonics Holdings, Inc. (NYSE:SENS) has announced the completion of the ENHANCE Pivotal Clinical Study for its 365-day Continuous Glucose Monitoring System. The study is designed to evaluate the accuracy and safety of the Eversense system for one year. The data gathered will be used to support the FDA submission for the system. The company aims to secure approval for the planned 365-day Eversense system in the coming quarters.
September 26, 2023 | 12:08 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Senseonics has completed a pivotal clinical study for its 365-day glucose monitoring system. The data will be used for FDA submission, aiming for approval in the coming quarters.
The completion of the clinical study is a significant milestone for Senseonics as it brings the company closer to FDA approval for its 365-day glucose monitoring system. If approved, this could potentially boost the company's market share and revenues, positively impacting the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100